As a result of these CV benefits, the 2022 American Diabetes Association (ADA) standards of medical care in diabetes clinical practice recommendations advise that an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated CVD benefit should be given as part of a regimen in patients with type 2 diabetes with established atherosclerotic CVD. This evidence concerns the gene GLP1R and diabetes mellitus.